We found that the NFκB pathway activity was higher in MM PC from newly diagnosed patients in the NFκB cluster compared to the other molecular clusters but observed no additional differences in NFκB pathway activity in relation to early disease development, patient prognosis, or response to first-line therapy. Here, NFKB1 is linked to Miyoshi myopathy.